Viromed Medical AG, a medical technology company specializing in cold plasma technology, announced the appointment of Prof. Dr. Michael A. Rubhausen to its Medical Advisory Board, effective immediately. The company, listed on the stock exchange since October 2022, aims to leverage Prof. Rubhausen's expertise in spectroscopy and materials research to further its scientific investigations.
Prof. Rubhausen heads the Optics Working Group at the Institute of Nanostructure and Solid-State Physics at Universität Hamburg and serves as the Institute's Managing Director. He is also affiliated with the Center for Free-Electron Laser Science (CFEL). His research focuses on modern spectroscopic methods, including Raman spectroscopy and ellipsometry, which he applies to study superconductors, quantum materials, and biological and inorganic samples at large-scale research facilities such as PETRA III and FLASH. His interdisciplinary work has resulted in over 180 publications with approximately 4,000 citations, including contributions to journals like Physical Review Letters, JACS, Angewandte Chemie, Nature Chemistry, Nature Physics, Cellular and Molecular Life Sciences, and Nature Communications. Additionally, he is involved in developing AI-supported analysis workflows for complex datasets.
Uwe Perbandt, CEO of Viromed Medical AG, commented: "With Prof. Dr. Michael A. Rubhausen, we are gaining a proven expert in modern spectroscopy and materials research for our Medical Advisory Board. His expertise is intended to help us thoroughly evaluate scientific questions at the intersection of material properties, spectroscopy, and cold plasma, and support our further research work."
This appointment underscores Viromed's commitment to advancing the medical applications of cold plasma technology. Cold plasma, an ionized gas, has shown potential in various medical fields, including wound healing, disinfection, and cancer treatment. By adding a physicist with deep knowledge of material properties and spectroscopy, Viromed aims to better understand how cold plasma interacts with biological tissues and materials, potentially leading to more effective and safer medical devices.
The Medical Advisory Board is expected to guide Viromed's research and development strategy, particularly in optimizing plasma sources and understanding the mechanisms of action. Professor Rubhausen's background in analyzing complex data and his experience with cutting-edge spectroscopic techniques could prove invaluable in characterizing plasma-treated surfaces and biological responses.
Viromed Medical AG, through its subsidiary Viromed Medical GmbH, distributes innovative cold plasma technology for medical applications in the DACH region and beyond. The company is focused on realizing growth potential by expanding the use of this technology in medicine.
The addition of Prof. Rubhausen signals Viromed's dedication to scientific rigor and innovation. For the medical community, this could lead to improved cold plasma-based therapies and a deeper understanding of their effects. For investors, it demonstrates the company's proactive approach to strengthening its advisory capabilities to support long-term value creation.
For more information about Viromed Medical AG, visit www.viromed-medical-ag.de.
